BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

NCT00656136 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

585

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: placebo
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim